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Background: Beta thalassemia major patients are vulnerable to transfusion-transmitted 
infection, especially hepatitis C virus (HCV), and iron overload. These comorbidities lead to 
cirrhosis and hepatocellular carcinoma in these patients. In order to prevent these complications, 
treatment of HCV infection and regular iron chelating seems to be necessary. The aim of this 
study was to evaluate the effect of hepatic iron concentration (HIC) and viral factors on the 
sustained virological response (SVR) in chronic HCV-infected patients, with beta thalassemia 
major being treated with interferon and ribavirin.
Materials and methods: We enrolled 30 patients with thalassemia major and chronic HCV 
who were referred to the Hematology Clinic of Guilan University of Medical Sciences, between 
December 2002 and April 2006. HIC was measured by atomic absorption spectroscopy before 
treatment. The viral factors (viral load, genotype) and HIC were compared between those who 
achieved a SVR and nonresponders.
Results: Mean age of the 30 thalassemic patients, was 22.56 ± 4.28 years (14–30 years). Most 
patients were male (56.7%). Genotype 1a was seen in 24 (80%) cases. SVR was achieved in 
15 patients (50%). There were no significant correlations between HIC (P = 1.00), viral load 
(P = 0.414), HCV genotype (P = 0.068), and SVR. No difference was observed in viral load 
(P = 0.669) and HIC (P = 0.654) between responders and nonresponders.
Conclusion: HIC, HCV viral load, and HCV genotype were not correlated with virological 
response, and it seems that there is no need to postpone antiviral treatment for more vigorous 
iron chelating therapy.
Keywords: hepatitis C virus, hepatic iron concentration, combination therapy, thalassemia 
major, interferon alfa, ribavirin
Introduction
Beta thalassemia is the most common inherited single gene disorder worldwide1 and 
one of the most common autosomal recessive disorders in Iran where there is tradition 
of inbreeding and a conservative culture; there are more than 15,000 registered cases 
in the country.2–4 It is caused by point mutations or, more rarely, deletions in the beta 
globin gene on chromosome 11. This often leads to a decreased or absent synthesis of 
the beta chains of hemoglobin. Patients usually present within the first 2 years of life 
with severe anemia, requiring regular red blood cell transfusions.5 The life-long need 
for transfusion renders patients vulnerable to transfusion-transmitted viral infections 
especially hepatitis C virus (HCV).6,7 Up to 80% of adult thalassemic patients are International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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infected with HCV infection worldwide.8 In Iran HCV infec-
tion rate ranges from 2% to 32%.9   Transfusion-dependent 
thalassemic patients have mild liver necroinflammation, 
mainly attributable to HCV infection. Significant fibrosis 
is frequent, and its progression is influenced mostly by 
iron overload which, with current therapy regimens, may 
be attributable to both erythrocyte catabolism and iron 
hyperabsorption.10,11 Iron overload and HCV infection are 
independent risk factors for liver fibrosis progression, and 
their concomitant presence results in a striking increase in 
risk.12,13 Aggressive approaches to the treatment of HCV may 
be particularly valuable because of the additive risks for cir-
rhosis and hepatocellular carcinoma that are posed by infec-
tion and iron overload.14 Nowadays, combination therapy with 
peginterferon (PEG-IFN) plus ribavirin (RBV) is the standard 
treatment for chronic HCV .15–17 In patients with chronic 
HCV and advanced fibrosis, sustained virologic response 
(SVR) to treatment is associated with improved clinical 
outcomes, mainly prevention of liver failure.18 In previous 
studies, it has been proved that the mentioned comorbidities 
such as iron overload negatively affect the outcome of liver 
disease, often reducing the chance of achieving a SVR with 
PEG-IFN and RBV treatments in chronic HCV patients.19–23 
Burt and Cooksley showed that a hepatic iron concentration 
(HIC) . 1100 µg/g appears to identify a group of patients 
who are unlikely to respond to IFN-α.24 Some studies have 
shown that raised ferritin values predicate nonresponse to 
IFN-RBV therapy in HCV patients.25,26 On the other hand, 
some authors have demonstrated that iron removal does not 
appear to improve responsiveness to IFN-α therapy.27–29 Some 
studies have shown the impact of iron on the outcome of IFN 
therapy and indicated that iron removal can improve the rate 
of response to IFN, especially in patients with lower hepatic 
iron deposits.30,31 There seems a low rate of treatment with 
IFN and RBV in thalassemic patients. The aim of this study 
was to evaluate the correlation between HIC and SVR in treat-
ment of chronic HCV infection in thalassemic patients.
Materials and methods
Among thalassemia major patients who were referred to 
Hematology Clinic of the Guilan University of Medical 
Sciences between December 2002 and April 2006, 30 patients 
who met the inclusion criteria and who were HCV RNA 
positive were studied.
In order to confirm the HCV status of subjects, anti-HCV 
antibody (anti-HCV Ab) was tested by third-generation 
enzyme-linked immunosorbent assay (ELISA, Diapro, Dia-
plus, Italy) and sera of these anti-HCV Ab-positive patients 
were analyzed by polymerase chain reaction (PCR, Roche 
Viral RNA kits, Germany) for detection of HCV RNA.
Exclusion criteria included: coinfection with HIV or 
hepatitis B virus, immunosuppression, previous antiviral 
therapy, chronic kidney disease, and alcohol consumption. 
Finally, after giving written informed consent, 30 beta thala-
ssemia major patients who were HCV RNA positive were 
enrolled. The protocol of this study conformed to the ethical 
guidelines of the Helsinki Declaration and was approved by 
the local ethical committee.
Sera from patients were analyzed by real time reverse 
transcription polymerase chain reaction assay (Qiagen, 
Germany) to determine viral load. Consecutively, HCV 
genotyping was performed by hybridization assay with a 
Qiagen kit. Viral load was defined as low at ,104 copies/mL; 
intermediate at 50 × 104 copies/mL, and high at .50 × 104 
copies/mL.
Liver biopsies were obtained from all patients before 
treatment. HIC was determined by atomic absorption 
spectroscopy in formalin-fixed, paraffin-embedded liver 
samples. The results were expressed as mmol/g dry tissue 
weight. The mean of two quantifications of iron by spec-
trometer was calculated and defined as HIC. Patients were 
divided into three groups according to HIC: low, dry tissue 
weight , 125 mmol/g; intermediate, dry tissue weight 125 to 
400 mmol/g; and high, dry tissue weight . 400 mmol/g.
A total of 30 treatment-naive patients with HCV 
  genotype 1a (n = 24) and 3a (n = 6) infection was enrolled 
into 48 weeks and 24 weeks of treatment with IFN-α-2a 
(3 million units 3 times weekly) plus RBV (1000–1200mg/
day, based on body weight), respectively. The HCV RNA was 
quantitatively assessed before treatment, after 12 weeks of 
treatment, and at end of treatment (48 weeks and 24 weeks 
respectively). The response to antiviral treatment was evalu-
ated by the detection of HCV RNA in serum by qualitative 
PCR at 12 weeks of treatment and end of treatment (48 weeks 
and 24 weeks respectively). Patients who tested HCV RNA 
negative at 12 weeks of treatment and end of treatment were 
classified as responders (SVR). All other patients, including 
those who relapsed, were classified as nonresponders. The 
patients were compared for HIC, viral load, and HCV 
genotype according to the response to treatment (SVR or 
nonresponders).
statistical analysis
Data were analyzed by using SPSS software version 15. 
Categorical variables were expressed as frequency and 
percentages. Continuous variables were expressed as mean International Journal of General Medicine 2011:4
Table 1 Demographic and clinical characteristics of the sample 
studied
Characteristic N = 30
sex
  Male 17
  Female 13
Age (years) 22.56 ± 4.28
Viral load (copies/mL) 333432 ± 422285
hIc (mmol/g) 157.34 ± 90.51
hcV genotype (%)
  1a 80
  3a 20
Note: Quantitative variables are expressed as mean ± sD.
Abbreviations: hcV, hepatitis c virus; hIc, hepatic iron concentration.
Table 2 Viral load, hcV genotype, and hepatic iron concentration 
(hIc)  in  patients  presenting  a  sustained  virological  response 
(sVr) and in nonresponders (nr)
SVR NR P value
Viral load (copies/mL)
  Low 1 (50) 1 (50) 0.414
  Intermediate 11 (45.8) 13 (54.2)
  high 3 (75) 1 (25)
hcV genotype
  1a 10 (41.7) 14 (58.3) 0.068
  3a 5 (83.3) 1 (16.7)
hIc (mmol/g)
  Low 7 (50) 7 (50) 1.00
  Intermediate 8 (50) 8 (50)
  high 0 (0) 0 (0)
Note: categorical variable expressed as number (percent).
Abbreviation: hcV, hepatitis c virus.
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and standard deviation or median and range. Continuous 
variables were compared by the t-test. The Pearson’s and 
Spearman’s correlations between HIC, viral load, and 
SVR were determined. A P value , 0.05 was considered 
  statistically significant.
Results
Mean age of the studied patients was 22.56 ± 4.28 years 
(14–30 years). Most patients were male (56.7%). HCV virus 
genotyping test resulted in type 1a in 24 (80%) and type 3a in 
6 (20%). SVR was achieved in 15 patients (50%) (Table 1).
 There was no significant correlation between viral load 
and SVR (P = 0.414), HIC and SVR (P =1.00), or between 
HCV genotype and SVR (P = 0.068) (Table 2). No difference 
was observed in viral load (P = 0.669) and HIC (P = 0.654) 
between responders and nonresponders (Table 3).
Discussion
HCV infection is often associated with an elevation of iron 
parameters. Free liver iron causes liver damage and liver fibrosis 
preferentially through induction of reactive oxygen species.31,32 
In addition, data suggest an effect of iron on the outcome of IFN 
therapy. Conflicting results have been reported in studies evalu-
ating the relationship between liver iron deposits in chronic 
HCV patients, and also their effect on the response to therapy 
in these patients.33–36 Tsai et al showed that 15% of chronic HCV 
patients who previously failed IFN had a sustained response to 
IFN therapy after iron depletion.23 Ortiz et al concluded that 
sustained response to IFN therapy is an infrequent event and 
is more dependent on viral factors (viral load and genotype) 
and lowering serum ferritin by phlebotomy does not increase 
HCV eradication rate after IFN treatment.28 Herrera showed 
that patients who previously failed treatment with IFN, iron 
depletion induced by phlebotomy is ineffective in achieving 
viral eradication in patients retreated with IFN.29
Van Thiel et al suggested that hepatic iron content predicts 
a response to IFN therapy. They showed that hepatic iron 
content of nonresponders was almost twice that of responders 
(1156 ± 283 µg/g dry weight vs 638 ± 118; P , 0.05).37 Olynyk 
et al showed that mean HIC in nonresponders (860 ± 100 µg/g) 
was significantly higher than in responders (548 ± 85 µg/g) 
(P , 0.05). They also found that patients with chronic HCV 
who have an HIC of . 1100 µg/g predicted nonresponse in 
88% of patients. Response to therapy in that study was defined 
as normalization of alanine transferase levels at the end of treat-
ment.38 In our study, correlation between HIC and SVR as well 
as viral factors and SVR were evaluated. Surprisingly, HIC in 
SVR (164.93 ± 95.06 mmol/g) was higher than nonresponders 
(149.76 ± 88.37 mmol/g), although there was no significant 
relationship between HIC and SVR. Nonresponsiveness may 
be related to definition of SVR in various studies.
Consistent with our findings, Sievert et al, in their study of 
28 patients with beta thalassemia major, found no difference 
in HIC between responders and nonresponders to therapy.39 
Pianko et al found that in the combination therapy (IFN and 
RBV) group, the mean HIC was similar for both SVR and 
nonresponders (533 ± 86 µg/g in the NR, and 662 ± 95 µg/g 
in the SVR).40 Rulyak et al showed no significant difference in 
median HIC between responders and nonresponders (404 µg/g 
Table 3   comparison  between  viral  load  and  hepatic  iron 
concentration (hIc) of responders and nonresponders (nr)
SVR NR P value
Viral load 367223 ± 532418 299640 ± 288912 0.669
hIc 164.93 ± 95.06 149.76 ± 88.37 0.654
Note: Quantitative variables expressed as mean ± sD.
Abbreviation: sVr, sustained virological response.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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and 394 µg/g, respectively; P = 0.31)41 Pereira et al found that 
median HIC was 9.9 and 8.2 µmol/g dry tissue (P = 0.51) for 
SVR and NR patients, respectively.42 Differences in median 
HIC between SVR and nonresponder groups in these studies 
may be associated with method of tissue staining and tech-
nique of determination of HIC. In contrast, Fujita et al found 
that increased hepatic iron stores in chronic HCV were related 
to resistance to IFN-RBV treatment.43 Lin et al suggested that 
positive hepatic iron stain is an independent predictor of non-
response to combination therapy with PEG-IFN-α and RBV 
for patients with chronic HCV .44 Bertino et al, in a study of 45 
patients with chronic HCV who were taking PEG-IFN-α-2a 
and RBV , found that HIC negatively conditions the response to 
therapy with PEG-IFN and RBV . In their study, iron removal 
was correlated with the response to treatment.45
Sievert et al showed that serum HCV RNA was lower 
in responders than in nonresponders and also showed 
that genotype 1 was more frequent in nonresponders, and 
nongenotypes 1 were more frequent in responders, although 
this was not statistically significant.39 Although in our study 
genotype 1a was more frequent (58.3%) in nonresponders, 
we found no correlation between HCV genotype and SVR, 
and we also found no   correlation between HCV viral load 
and SVR. Souza et al studied 85 patients with chronic HCV 
who were treated with IFN and RBV and found no associa-
tion between HCV genotype and response to IFN and RBV 
therapy.46 De Galocsy et al indicated that many genotype 
4 HCV patients in Belgium originate from Central Africa, 
and their response to treatment seems lower.47 Alavian et al 
suggested in their review of 13 articles which included 429 
thalassemic HCV-infected patients treated with conventional 
or combination therapy with RBV that genotype 1 infection 
significantly benefits from combination therapy with riba-
virin.48 Rulyak et al indicated that factors associated with 
SVR included genotype 2 or 3 (odds ratio [OR] = 12.2; 95% 
confidence interval [CI] 3.1–47.8) and viral load , 2 million 
copies/mL (OR = 3.6; 95% CI 1.3–10.0).41 Effect of viral fac-
tors on anti-HCV treatment may be associated with patient 
factors such as their immune status and duration of treatment. 
Results of the Jurczyk et al study showed that iron status 
does not significantly influence the efficacy of treatment with 
IFN and RBV in patients with chronic HCV .49 Taliani et al, 
who studied retreatment of nonresponders to IFN and RBV 
in HCV-infected patients, showed that accurate selection of 
patients, such as those with low viral load and low gamma-
glutamyltransferase levels, and prolongation of therapy for 
more than 24 weeks also in HCV RNA-positive patients, may 
further increase the rate of SVR.50
In conclusion, our study indicated that HIC, HCV viral 
load, and HCV genotype were not correlated with virological 
response to antiviral treatment, and it seems that there may 
be no need to postpone antiviral treatment for more vigorous 
iron chelating therapy and reducing hepatic iron overload.
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